Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

How effective is natalizumab induction therapy in patients with Crohn's disease?

Nature Clinical Practice Gastroenterology & Hepatology volume 5, pages 78–79 (2008)Cite this article

boxed-textTargan SR et al. (2007) Natalizumab for the treatment of active Crohn's disease: results of the ENCORE trial. Gastroenterology 132: 1672–1683

Natalizumab induces remission only in a minority of patients with Crohn's disease and has serious adverse effects; therefore, natalizumab is not a recommended treatment for Crohn's disease

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Ghosh S et al. (2003) Natalizumab for active Crohn's disease. N Engl J Med 348: 24–32

    Article  CAS  Google Scholar 

  2. Sandborn WJ et al. (2005) Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 353: 1912–1925

    Article  CAS  Google Scholar 

  3. Van Assche G et al. (2005) Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 353: 362–368

    Article  CAS  Google Scholar 

  4. Fellermann K et al. (2003) Crohn's disease: a defensin deficiency syndrome? Eur J Gastroenterol Hepatol 15: 627–634

    Article  CAS  Google Scholar 

  5. Wehkamp J et al. (2005) Mechanisms of disease: defensins in gastrointestinal diseases. Nat Clin Pract Gastroenterol Hepatol 2: 406–415

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Rachel Jones, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. and EF Stange is Head of the Department of Internal Medicine I, K Fellermann is a Senior House Officer, both at Robert Bosch Hospital, Stuttgart, Germany.,

    Klaus Fellermann & Eduard F Stange

Authors
  1. Klaus Fellermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eduard F Stange
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eduard F Stange.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fellermann, K., Stange, E. How effective is natalizumab induction therapy in patients with Crohn's disease?. Nat Rev Gastroenterol Hepatol 5, 78–79 (2008). https://doi.org/10.1038/ncpgasthep1031

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpgasthep1031

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing